Author:
Alenzi Maram,Almeqdadi Mohammad
Abstract
Hepatitis C virus (HCV) is a significant public health challenge globally, with substantial morbidity and mortality due to chronic liver disease. Despite the availability of highly effective and well-tolerated direct-acting antiviral therapies, widespread disparities remain in hepatitis C screening, access to treatment, linkage to care, and therapeutic outcomes. This review article synthesizes evidence from various studies to highlight the multifactorial nature of these disparities, which affects ethnic minorities, people with lower socioeconomic status, individuals with substance use disorders, and those within correctional facilities. The review also discusses policy implications and targeted strategies needed to overcome barriers and ensure equitable care for all individuals with HCV. Recommendations for future research to address gaps in knowledge and evaluation of the effectiveness of interventions designed to reduce disparities are provided.
Publisher
Baishideng Publishing Group Inc.
Reference48 articles.
1. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study
2. Center for Disease Control and Prevention Viral hepatitis surveillance. Number of reported cases of acute Hepatitis C virus infection and estimated infections-United States, 2014–2021. Available from: https://www.cdc.gov/hepatitis/statistics/2021surveillance/hepatitis-c/figure-3.1.htm
3. WHO. Global hepatitis report 2024: action for access in low- and middle-income countries. Available from: https://www.who.int/publications/i/item/9789240091672
4. Overcoming barriers to hepatitis C elimination
5. Patient and provider‐level barriers to hepatitis C screening and linkage to care: A mixed‐methods evaluation